Poor efficacy clouds prospects for the company's "improved" Yervoy.

The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.

The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.

First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.

Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.